US Patent

US9585883 — Pyrimidinedione compounds

Method of Use · Assigned to Myokardia Inc · Expires 2034-06-19 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel pyrimidine dione compounds and their salts for treating hypertrophic cardiomyopathy and related heart conditions.

USPTO Abstract

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3373 — Camzyos
U-3373 — Camzyos
U-3373 — Camzyos
U-3373 — Camzyos

Patent Metadata

Patent number
US9585883
Jurisdiction
US
Classification
Method of Use
Expires
2034-06-19
Drug substance claim
No
Drug product claim
No
Assignee
Myokardia Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.